1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ
Nuvectis Pharma Establishes At The Market Offering Program
Reports Second Quarter 2026 Financial Results and Business Highlights
Announces Pricing of $100 Million Public Offering of Common Stock
Other Events
Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In-Class Clinical-Stage Compounds
Correction of Outstanding Shares at Nuvectis Pharma's Annual Meeting
Reports First Quarter 2026 Financial Results and Business Highlights
Reports 2025 Financial Results and Business Highlights
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
SEC Staff Correspondence
S-1MEF